Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998;12(4):218-22.
doi: 10.1002/(sici)1098-2825(1998)12:4<218::aid-jcla5>3.0.co;2-3.

Calcitonin levels in normal individuals with new highly sensitive chemiluminescent enzyme immunoassay

Affiliations

Calcitonin levels in normal individuals with new highly sensitive chemiluminescent enzyme immunoassay

H Suzuki. J Clin Lab Anal. 1998.

Erratum in

  • J Clin Lab Anal 1998;12(5):325

Abstract

Human serum calcitonin concentration in normal individuals was measured with a new assay based on the chemiluminescent enzyme immunoassay (CLEIA) method. The CLEIA assay was highly sensitive and was able to determine a calcitonin concentration of 0.04 pg/ml as sensitivity limit at a condition of 0+3SD. With this CLEIA assay, the mean value of calcitonin in males and females was 2.26 and 1.33 pg/ml, respectively, highlighting a significant difference between genders. The mean value and range of human serum calcitonin in this assay were approximately 1/10 those reported previously in competitive radioimmunoassay (RIA) methods. Since RIAs for calcitonin showed much variability at a low concentration range due to the competitive format, they seemed to lack the necessary sensitivity to cover the normal range and appeared only useful for hyper-calcitonin phenomenon in diseases such as medullary thyroid carcinoma. The CLEIA for calcitonin provided a lower detection limit than normal range, and it can therefore be assumed that it could be applied for the measurement of hypo-calcitonin phenomena typically found in some disorders such as osteoporosis.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Tashijian AH, Howland BG, Melvin KEW, Hill CS: Immunoassay of human calcitonin: Clinical measurement relation to serum calcitonin and studies in patients with medullary carcinoma. N Engl J Med 283: 890–6, 1970. - PubMed
    1. Body J‐J, Health H III: Estimation of circulating monomeric calcitonin: Physiological study in normal and thyroidectomized man. J Clin Endocrinol Metab 57: 897–903, 1983. - PubMed
    1. Gharib H, Kao PC, Health H III: Determination of silica‐purified calcitonin for the detection and management of medullary thyroid carcinoma: Comparison of two provocative tests. Mayo Clin Proc 62: 373–378, 1987. - PubMed
    1. Motte P, Vauzelle P, Gardet P, et al.: Construction and clinical validation of a sensitive and specific assay for serum calcitonin using monoclonal antipeptide antibodies. Clin Chem Acta 174: 35–54, 1988. - PubMed
    1. Guilloteau D, Perdrisot R, Calmettes C, et al.: Diagnosis of medullary carcinoma of the thyroid (MCT) by calcitonin assay using monoclonal antibodies: Criteria for the pentagastrin stimulation test in hereditary MCT. J Clin Endcrinol Metab 71: 1064–1067, 1990. - PubMed

LinkOut - more resources